ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 19.47% |
2INCY | INCYTE CORP | Healthcare | $24.81B | 10.17% |
3GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 8.59% |
4BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 6.24% |
5OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 4.07% |
6PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 3.60% |
7TXG | 10X GENOMICS INC | Healthcare | $7.77B | 3.19% |
8IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 2.97% |
9CAI | CARIS LIFE SCIENCES INC | Healthcare | $6.87B | 2.82% |
10KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 2.79% |
11BLLN | BILLIONTOONE INC | Healthcare | $5.29B | 2.17% |
12SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 2.16% |
13LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 2.15% |
14VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 1.44% |
15PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 1.40% |
16AXGN | AXOGEN INC | Healthcare | $3.31B | 1.36% |
17DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 1.31% |
18PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.24B | 0.92% |
19IMNM | IMMUNOME INC | Healthcare | $2.21B | 0.91% |
20REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.85% |
21TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 0.84% |
22HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.81% |
23COAG | HEMAB THERAPEUTICS HOLDINGS INC | Healthcare | $1.84B | 0.75% |
24BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.73% |
25NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.70% |
26SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.66% |
27IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.65% |
28ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.64% |
29ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.59% |
30KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.58% |
31OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.57% |
32LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.56% |
33TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.56% |
34DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.56% |
35AVLN | AVALYN PHARMA INC | Healthcare | $1.36B | 0.56% |
36PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.35B | 0.55% |
37KARD | KARDIGAN INC | Healthcare | $1.32B | 0.54% |
38CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.53% |
39INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.53% |
40ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.50% |
41SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.46% |
42MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.45% |
43IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.45% |
44VSTM | VERASTEM INC | Healthcare | $1.06B | 0.44% |
45CTY | CITY THERAPEUTICS INC | Healthcare | $955M | 0.39% |
46OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.37% |
47LTGO | LATIGO BIOTHERAPEUTICS INC | Healthcare | $857M | 0.35% |
48BBTX | BAMBUSA THERAPEUTICS INC | Healthcare | $834M | 0.34% |
49IAM | IAMBIC THERAPEUTICS INC | Healthcare | $703M | 0.29% |
50NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.29% |
51APMD | APNIMED INC | Healthcare | $692M | 0.28% |
52SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.28% |
53CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.26% |
54SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.25% |
55SRZN | SURROZEN INC | Healthcare | $604M | 0.25% |
56IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.24% |
57AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 0.23% |
58ETRA | ELECTRA THERAPEUTICS INC | Healthcare | $557M | 0.23% |
59CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.22% |
60PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.21% |
61BLSM | BLOSSOMHILL THERAPEUTICS INC | Healthcare | $472M | 0.19% |
62MOBI | MOBIA MEDICAL INC | Healthcare | $444M | 0.18% |
63PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.17% |
64TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.17% |
65FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.16% |
66SCTX | SCRIBE THERAPEUTICS INC | Healthcare | $322M | 0.13% |
67BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.13% |
68CV | CAPSOVISION INC | Healthcare | $314M | 0.13% |
69TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.13% |
70QTTB | Q32 BIO INC | Healthcare | $264M | 0.11% |
71ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.10% |
72UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.10% |
73DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.09% |
74GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.09% |
75AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.08% |
76TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.08% |
77KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.08% |
78RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.08% |
79ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.08% |
80CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.05% |
81SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.05% |
82IMUX | IMMUNIC INC | Healthcare | $106M | 0.04% |
83RTSN | RETENSION PHARMACEUTICALS INC | Healthcare | $97M | 0.04% |
84JYNT | JOINT CORP | Healthcare | $92M | 0.04% |
85RLYB | RALLYBIO CORP | Healthcare | $84M | 0.03% |
86VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.03% |
87NRXS | NEURAXIS INC | Healthcare | $82M | 0.03% |
88NTRB | NUTRIBAND INC | Healthcare | $73M | 0.03% |
89GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.03% |
90XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.02% |
91COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.02% |
92YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.02% |
93ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.02% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $243.97B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 81% toward Large, 66% toward Growth. +20% unclassified (18 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 21%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 12.5% | -5.9% |
| 3 yearsp.a. | 21.2% | 2.9% |
| 5 yearsp.a. | 1.6% | -7.5% |
| 10 yearsp.a. | 2.4% | -7.4% |
| Since inceptionp.a. | 1.2% | -5.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 14.6% | -6.7% |
| 2025 | 43.3% | 22.1% |
| 2024 | -6.6% | -15.4% |
| 2023 | 19.3% | 16.7% |
| 2022 | -32.1% | -22.8% |
| 2021 | -45.7% | -57.9% |
| 2020 | 44.7% | 34.2% |
| 2019 | 32.2% | 11.0% |
| 2018 | -16.0% | -18.6% |
| 2017 | 22.3% | 9.9% |
| 2016 | -23.6% | -11.7% |
| 2015 | 2.6% | -1.9% |
| 2014 | 34.6% | 12.3% |
| 2013 | 39.1% | -8.1% |
| 2012 | 30.4% | 12.7% |
| 2011 | -0.6% | -7.1% |
| 2010 | 10.0% | 3.7% |
| 2009 | 17.1% | -6.0% |
| 2008 | -29.0% | -2.5% |
| 2007 | -4.9% | -7.1% |
| 2006 | 8.9% | -1.0% |
| 2005 | 2.7% | 1.5% |
| 2004 | -5.4% | 3.2% |
| 2003 | 36.1% | 14.8% |
| 2002 | -41.4% | -28.3% |
| 2001 | -22.3% | -19.4% |
| 2000 | -27.4% | -51.4% |
| 1999 | 34.7% | 62.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Cash Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Cash signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.